Recent study finds that 84% of adults with congenital heart disease reported good or better quality of life, with notable findings on physical activity and mental health.
The article delves into the crisis facing 25,000 U.S. patients who rely on parenteral nutrition due to their inability to digest food, exacerbated by CVS's exit from the business and compounded by supply shortages.
FDA approves Avadel Pharmaceuticals' once-nightly dosing sleep disorder drug, Lumryz, for children aged 7 years and older, offering a new option for narcolepsy treatment.
Study unveils significant association between familial hypercholesterolemia and type 2 diabetes risk, with obesity as the primary contributor. Higher prevalence observed in the Eastern Mediterranean region.
Conexiant
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
EULAR's latest recommendations for systemic sclerosis treatment include 22 evidence-based guidelines across 8 clinical domains, marking a significant expansion from the 16 recommendations in 2017.
With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.
New once-weekly subcutaneous anti-TFPI therapy for hemophilia A and B reduces annualized bleeding rate by 35% vs. routine prophylaxis and 92% vs. on-demand treatment in patients without inhibitors.
A new study in The New England Journal of Medicine reveals promising results for patients with persistent chylomicronemia, suggesting that plozasiran may reduce triglyceride levels by up to 80% and lower the risk of acute pancreatitis.